Celgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial benefit from it. Otezla (apremilast)—an oral PDE4 inhibitor—has been ...

If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...